Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 12Recurrence 1Neoplasms, Plasma Cell 1Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

Dexamethasone 7Calcium Dobesilate 5Filgrastim 4Cyclophosphamide 4miridesap 3ixazomib 3dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Peripheral Blood Stem Cell Transplantation 3Bortezomib 3venetoclax 2Tacrolimus 2Methylprednisolone 2Amifostine 2sargramostim 1pyroxamide 1pomalidomide 1nelarabine 1melflufen 1isatuximab 1fludarabine phosphate 1daratumumab 1X-Rays 1Topotecan 1Tetradecanoylphorbol Acetate 1Technetium Tc 99m Pyrophosphate 1Technetium 1Sunitinib 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Immunoglobulin Light-chain Amyloidosis × isatuximab × Clear all
NCT04754945 2026-02-18

Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

Emory University

Phase 1 Active not recruiting
11 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡